Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Bids To Stop Samsung Bioepis’ Etanercept In Australia

Brenzys Biosimilar Products Listed On Australia’s PBS Since April 2017

Executive Summary

Enbrel (etanercept) originator Pfizer has filed suit in Australia over the sale of Samsung Bioepis’ rival Brenzys biosimilar. It alleges that it has “suffered, and will continue to suffer, substantial loss and damage.”

You may also be interested in...



Amgen’s Bevacizumab Biosimilar Is Alone On Australia’s PBS

US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.

Organon Completes Spin-Out From Merck With Five Biosimilars

With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.

Australia’s PBS Lists Four Adalimumab Biosimilars

Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel